Trastuzumab, a humanised IgG monoclonal antibody targeting HER2 directly, has been evaluated for its efficacy in advanced NSCLC patients with HER-2/neu positivity across various chemotherapy regimens. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.